|Healthcare Review: OXiGENE, Biosante Pharmaceuticals, Targacept, AEterna Zentaris Are Top Gainers|
|By Staff and Wire Reports|
|Tuesday, 18 September 2012 14:52|
OXiGENE, Inc.(NASDAQ:OXGN) shares jumped 24.99% to $0.686 after the company announced yesterday that it has come to agreement with the U.S. Food and Drug Administration or FDA on a Special Protocol Assessment or SPA for its Phase 3 clinical trial or FACT 2 of Zybrestat for the treatment of anaplastic thyroid cancer or ATC.
The company noted that the FACT 2 study is designed as a randomized, placebo-controlled, double-blinded study of 300 subjects randomized 1:1 to receive carboplatin and paclitaxel plus fosbretabulin versus carboplatin and paclitaxel plus placebo.
Biosante Pharmaceuticals Inc (NASDAQ:BPAX) shares climbed 12.89% to $2.12. The company announced that the independent Data Monitoring Committee or DMC has completed the ninth unblinded review of the LibiGel Phase III cardiovascular events and breast cancer safety study. The independent DMC has recommended that the LibiGel safety study should continue as per the FDA-agreed protocol, without modifications. LibiGel is in development for the treatment of female sexual dysfunction or FSD, specifically, hypoactive sexual desire disorder or HSDD in menopausal women.
Targacept , Inc.(NASDAQ:TRGT) shares gained 8.61% to $4.68. The company yesterday said that it will no longer develop TC-5619 as a treatment for adults with inattentive-predominant attention deficit/hyperactivity disorder, because the drug didn't meet the primary endpoints of a Phase II study. Additionally, the company said it will cut more jobs and limit investments to its ongoing or previously announced clinical programs until it finds a new chief executive. Further details weren't disclosed.
AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) shares increased 11.43% to $0.700 in the morning hour. The company, on Sept. 7, said that it has recruited the first patient for a Phase IIA trial with its ghrelin agonist, AEZS-130 in patients with cancer cachexia. The study is conducted under a Cooperative R&D Agreement, or CRADA, between Aeterna Zentaris and the Michael DeBakey Veterans Affairs Medical Center which is funding the study.
Sequenom, Inc.(NASDAQ:SQNM) stock fell 0.25% to $3.98 after the company yesterday announced the completion of its offering of $130.0 million aggregate principal amount of 5.00% Convertible Senior Notes due 2017 in a private offering, including $20.0 million aggregate principal amount of notes sold pursuant to the full exercise of an over-allotment option previously granted to the initial purchasers.